NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/05/2026
Voltar para busca
Dado oficial do USPTO
HUMABODY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
44
Atualização mais recente
15/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 40, 42, 45
Data de depósito
12/08/2021
Data de registro
30/05/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/05/2023
Última transação
15/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
GB
Examinador
RILEY, KATHERINE M
Unidade examinadora
M80
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "HUMABODY" in a stylized font.
Titulares e representantes
Titulares
Crescendo Biologics Limited
Representantes
Matthew L. Frisbee Leason Ellis LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in industry and science; Chemicals for use in science and industrychemicals for laboratory research purposes; chemicals for use in science and industrychemicals for use in medical research; chemicals for use in science and industrychemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicalsmonoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicalsantibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicalsmonoclonal antibodies and antibody fragments for use in medical research; biochemicalsmonoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicalsmonoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discoverypreclinical developmentclinical development and manufacture of therapeutic products
Classe 5
Pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; veterinary preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodiesbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; antibody fragmentsbeing pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; therapeutic preparations that use monoclonal antibodiesnamely therapeutic pharmaceutical for treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseasesfor medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases for use in the discoverypreclinical and clinical development of therapeutic products for medical and veterinary purposes; pharmaceutical preparations for use in oncology; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancerautoimmune diseasesinflammatory conditionsallergies and allergic conditionshypersensitivity reactionsinfectionsorgan transplant rejectiontissue transplant rejectioncardiovascular diseasesneurological disordersdegenerative disordersmetabolic disordersdermatological diseases for use in oncology and therapeutic treatments in relation thereto
Classe 40
Custom manufacture of chemicalsbiologicalsantibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragmentsfor othersfor use in medical therapiesincluding in relation to oncology; consultancyadvice and information relating to all of the aforesaid services
Classe 42
Scientific and technological servicesresearch and design in the field of chemicalsbiologicalsantibodies and antibody fragments; scientific laboratory research services relating to the development of antibodies and antibody fragments; oncological research; research into the development of antibodies and antibody fragments; scientific and technological servicesprovision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicalsbiologicalsantibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific servicesdiscoverypreclinical and clinical development of therapeutic products; scientific research for others in the field of drug discoverypreclinical and clinical development of therapeutic and diagnostic products; research into antibodiesantibody fragments for others; research into the formationmanufacturemedical usage and manipulation of antibodies and antibody fragments for others; consultancyadvice and information relating to all of the aforesaid services
Classe 45
Licensing of intellectual propertylicensing of research and development; licensing of intellectual propertylicensing of medical therapeutic research; licensing of intellectual propertylicensing of research relating to antibodies and antibody fragments; licensing of intellectual propertylicensing of research in relation to the formationmanufacturemedical usage and manipulation of antibodies and antibody fragments; consultancyadvice and information relating to all of the aforesaid services
Publicações
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/06/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/06/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/06/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
03/06/2025
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
08/11/2024
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
27/10/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
25/09/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
31/08/2023
FIMP
FINAL DISPOSITION PROCESSED
31/08/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/08/2023
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
19/08/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/05/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
30/05/2023
GPNX
NOTIFICATION PROCESSED BY IB
15/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/03/2023
PUBO
PUBLISHED FOR OPPOSITION
14/03/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/02/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/02/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/02/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
03/02/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/02/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
03/02/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/02/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
16/12/2022
GNFR
FINAL REFUSAL E-MAILED
16/12/2022
CNFR
FINAL REFUSAL WRITTEN
16/12/2022
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
15/11/2022
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
15/11/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/10/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/10/2022
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
14/10/2022
RFNT
REFUSAL PROCESSED BY IB
13/07/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
10/07/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/06/2022
RFRR
REFUSAL PROCESSED BY MPU
16/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
24/05/2022
CNRT
NON-FINAL ACTION WRITTEN
23/05/2022
DOCK
ASSIGNED TO EXAMINER
13/05/2022
MAFR
APPLICATION FILING RECEIPT MAILED
08/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/02/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/02/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HUMABODY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.